Human Antibodies Targeting Influenza B Virus Neuraminidase Active Site Are Broadly Protective

• Published in: Immunity (Cambridge, Mass.) Vol. 53; no. 4; pp. 852 - 863.e7
• Main Authors: Madsen, Anders, Dai, Ya-Nan, McMahon, Meagan, Schmitz, Aaron J., Turner, Jackson S., Tan, Jessica, Lei, Tingting, Alsoussi, Wafaa B., Strohmeier, Shirin, Amor, Mostafa, Mohammed, Bassem M., Mudd, Philip A., Simon, Viviana, Cox, Rebecca J., Fremont, Daved H., Krammer, Florian, Ellebedy, Ali H.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 13.10.2020; Elsevier Limited
• Subjects: Animals; Antibodies; Antibodies, Monoclonal - immunology; Antibodies, Viral - immunology; Antiviral agents; Antiviral drugs; B cells; Catalytic Domain - immunology; Cell Line; Dogs; Drug dosages; Enzymatic activity; Enzymes; Exo-a-sialidase; Female; HEK293 Cells; Human; Humans; Infection; Infections; Influenza; Influenza A; Influenza A virus - immunology; Influenza B; Influenza B virus; Influenza B virus - immunology; Influenza, Human - immunology; Leukocytes, Mononuclear - immunology; Madin Darby Canine Kidney Cells; Mice; Mice, Inbred BALB C; Middle Aged; Monoclonal antibodies; Neuraminidase; Neuraminidase - immunology; Orthomyxoviridae Infections - immunology; Plasmablasts; Proteins; Vaccines; Viral Proteins - immunology; Viruses; New York; Thailand; United States > US; Phuket Thailand; Human; Infection; Plasmablasts; Neuraminidase; Monoclonal antibodies; Influenza B virus; B cells

Influenza B virus (IBV) infections can cause severe disease in children and the elderly. Commonly used antivirals have lower clinical effectiveness against IBV compared to influenza A viruses (IAV). Neuraminidase (NA), the second major surface protein on the influenza virus, is emerging as a target...